Evolus Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Evolus stock.
View analyst ratings for Evolus or view top-rated stocks.

6 brokers have issued 1 year target prices for Evolus' stock. Their EOLS stock forecasts range from $10.00 to $20.00. On average, they expect Evolus' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts.

Evolus' stock was trading at $6.51 at the beginning of 2022. Since then, EOLS shares have increased by 79.6% and is now trading at $11.69.
View the best growth stocks for 2022 here.

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Evolus.

Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.24. The firm earned $33.90 million during the quarter, compared to analyst estimates of $29.83 million. Evolus had a negative trailing twelve-month return on equity of 80.20% and a negative net margin of 58.28%. The company's revenue was up 177.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share.
View Evolus' earnings history.

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $148.47 million.

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolus include Insmed (INSM), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), EQRx (EQRX), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Arcus Biosciences (RCUS), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR) and Dynavax Technologies (DVAX).
View all of EOLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $11.69.

Evolus (NASDAQ:EOLS) has a market capitalization of $655.21 million and generates $99.67 million in revenue each year. The company earns $-46.81 million in net income (profit) each year or ($1.30) on an earnings per share basis.

Evolus employs 167 workers across the globe.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for Evolus is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at [email protected].